Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Absolute Bioavailability of Bevurogant (BI 730357) in Healthy Volunteers
NCT03804671Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevurogant in plaque psoriasis, sponsored by Boehringer Ingelheim. Primary endpoint: Area Under the Concentration-time Curve from 0 to Infinity at 168 hours. Started Jan 2019; status: completed.
02
Drugs
bevurogant
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03804671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03804671.